HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
Want to see GB:HEMO full AI Analyst Report?
Total Valuation
HemoGenyx Pharmaceuticals Plc has a market cap or net worth of £54.40M. The enterprise value is 47.88M .
Market Cap£54.40M
Enterprise Value47.88M
Share Statistics
HemoGenyx Pharmaceuticals Plc has 6,799,961 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,799,961
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
HemoGenyx Pharmaceuticals Plc’s return on equity (ROE) is -8.16 and return on invested capital (ROIC) is -148.02%.
Return on Equity (ROE)-8.16
Return on Assets (ROA)-2.34
Return on Invested Capital (ROIC)-148.02%
Return on Capital Employed (ROCE)-1.72
Revenue Per Employee0.00
Profits Per Employee-610.45K
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of HemoGenyx Pharmaceuticals Plc is ―. HemoGenyx Pharmaceuticals Plc’s PEG ratio is -0.09.
PE Ratio―
PS Ratio0.00
PB Ratio21.26
Price to Fair Value21.26
Price to FCF-7.36
Price to Operating Cash Flow-14.02
PEG Ratio-0.09
Income Statement
In the last 12 months, HemoGenyx Pharmaceuticals Plc had revenue of 0.00 and earned -9.76M in profits. Earnings per share was -2.20.
Revenue0.00
Gross Profit-588.75K
Operating Income-4.66M
Pretax Income-9.77M
Net Income-9.76M
EBITDA-4.07M
Earnings Per Share (EPS)-2.20
Cash Flow
In the last 12 months, operating cash flow was -3.45M and capital expenditures -3.92K, giving a free cash flow of -3.45M billion.
Operating Cash Flow-3.45M
Free Cash Flow-3.45M
Free Cash Flow per Share-0.51
Dividends & Yields
HemoGenyx Pharmaceuticals Plc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.31
52-Week Price Change350.70%
50-Day Moving Average787.68
200-Day Moving Average841.21
Relative Strength Index (RSI)58.22
Average Volume (3m)113.41K
Important Dates
HemoGenyx Pharmaceuticals Plc upcoming earnings date is Sep 24, 2026, TBA (Confirmed).
Last Earnings DateApr 30, 2026
Next Earnings DateSep 24, 2026
Ex-Dividend Date―
Financial Position
HemoGenyx Pharmaceuticals Plc as a current ratio of 1.38, with Debt / Equity ratio of 167.66%
Current Ratio1.38
Quick Ratio1.38
Debt to Market Cap0.00
Net Debt to EBITDA-0.10
Interest Coverage Ratio-20.30
Taxes
In the past 12 months, HemoGenyx Pharmaceuticals Plc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
HemoGenyx Pharmaceuticals Plc EV to EBITDA ratio is -6.34, with an EV/FCF ratio of -7.48.
EV to Sales0.00
EV to EBITDA-6.34
EV to Free Cash Flow-7.48
EV to Operating Cash Flow-7.49
Balance Sheet
HemoGenyx Pharmaceuticals Plc has £1.59M in cash and marketable securities with £2.00M in debt, giving a net cash position of -£417.82K billion.
Cash & Marketable Securities£1.59M
Total Debt£2.00M
Net Cash-£417.82K
Net Cash Per Share-£0.06
Tangible Book Value Per Share£0.22
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for HemoGenyx Pharmaceuticals Plc is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-28.29%